144 related articles for article (PubMed ID: 31511612)
1. Fusion driven JMML: a novel CCDC88C-FLT3 fusion responsive to sorafenib identified by RNA sequencing.
Chao AK; Meyer JA; Lee AG; Hecht A; Tarver T; Van Ziffle J; Koegel AK; Golden C; Braun BS; Sweet-Cordero EA; Smith CC; Dvorak CC; Loh ML; Stieglitz E
Leukemia; 2020 Feb; 34(2):662-666. PubMed ID: 31511612
[No Abstract] [Full Text] [Related]
2. CCDC88C-FLT3 gene fusion in CD34-positive haematopoietic stem and multilineage cells in myeloid/lymphoid neoplasm with eosinophilia.
Kurihara Y; Mizuno H; Honda A; Shimura A; Fujioka Y; Maki H; Kurokawa M
J Cell Mol Med; 2022 Feb; 26(3):950-952. PubMed ID: 35019216
[No Abstract] [Full Text] [Related]
3. Role of mutation independent constitutive activation of FLT3 in juvenile myelomonocytic leukemia.
de Vries AC; Stam RW; Schneider P; Niemeyer CM; van Wering ER; Haas OA; Kratz CP; den Boer ML; Pieters R; van den Heuvel-Eibrink MM
Haematologica; 2007 Nov; 92(11):1557-60. PubMed ID: 18024405
[TBL] [Abstract][Full Text] [Related]
4. Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML.
Yoshimi A; Balasis ME; Vedder A; Feldman K; Ma Y; Zhang H; Lee SC; Letson C; Niyongere S; Lu SX; Ball M; Taylor J; Zhang Q; Zhao Y; Youssef S; Chung YR; Zhang XJ; Durham BH; Yang W; List AF; Loh ML; Klimek V; Berger MF; Stieglitz E; Padron E; Abdel-Wahab O
Blood; 2017 Jul; 130(4):397-407. PubMed ID: 28576879
[TBL] [Abstract][Full Text] [Related]
5. Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.
Baker SD; Zimmerman EI; Wang YD; Orwick S; Zatechka DS; Buaboonnam J; Neale GA; Olsen SR; Enemark EJ; Shurtleff S; Rubnitz JE; Mullighan CG; Inaba H
Clin Cancer Res; 2013 Oct; 19(20):5758-68. PubMed ID: 23969938
[TBL] [Abstract][Full Text] [Related]
6. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With
Burchert A; Bug G; Fritz LV; Finke J; Stelljes M; Röllig C; Wollmer E; Wäsch R; Bornhäuser M; Berg T; Lang F; Ehninger G; Serve H; Zeiser R; Wagner EM; Kröger N; Wolschke C; Schleuning M; Götze KS; Schmid C; Crysandt M; Eßeling E; Wolf D; Wang Y; Böhm A; Thiede C; Haferlach T; Michel C; Bethge W; Wündisch T; Brandts C; Harnisch S; Wittenberg M; Hoeffkes HG; Rospleszcz S; Burchardt A; Neubauer A; Brugger M; Strauch K; Schade-Brittinger C; Metzelder SK
J Clin Oncol; 2020 Sep; 38(26):2993-3002. PubMed ID: 32673171
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of sorafenib in FLT3-driven leukemic cells.
Auclair D; Miller D; Yatsula V; Pickett W; Carter C; Chang Y; Zhang X; Wilkie D; Burd A; Shi H; Rocks S; Gedrich R; Abriola L; Vasavada H; Lynch M; Dumas J; Trail PA; Wilhelm SM
Leukemia; 2007 Mar; 21(3):439-45. PubMed ID: 17205056
[TBL] [Abstract][Full Text] [Related]
9. Partial Response to Sorafenib in a Child With a Myeloid/Lymphoid Neoplasm, Eosinophilia, and a ZMYM2-FLT3 Fusion.
Munthe-Kaas MC; Forthun RB; Brendehaug A; Eek AK; Høysæter T; Osnes LTN; Prescott T; Spetalen S; Hovland R
J Pediatr Hematol Oncol; 2021 May; 43(4):e508-e511. PubMed ID: 32852395
[TBL] [Abstract][Full Text] [Related]
10. Integrated molecular profiling of juvenile myelomonocytic leukemia.
Murakami N; Okuno Y; Yoshida K; Shiraishi Y; Nagae G; Suzuki K; Narita A; Sakaguchi H; Kawashima N; Wang X; Xu Y; Chiba K; Tanaka H; Hama A; Sanada M; Ito M; Hirayama M; Watanabe A; Ueno T; Kojima S; Aburatani H; Mano H; Miyano S; Ogawa S; Takahashi Y; Muramatsu H
Blood; 2018 Apr; 131(14):1576-1586. PubMed ID: 29437595
[TBL] [Abstract][Full Text] [Related]
11. Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.
Zhang W; Gao C; Konopleva M; Chen Y; Jacamo RO; Borthakur G; Cortes JE; Ravandi F; Ramachandran A; Andreeff M
Clin Cancer Res; 2014 May; 20(9):2363-74. PubMed ID: 24619500
[TBL] [Abstract][Full Text] [Related]
12. FMS-Like Tyrosine Kinase 3 Inhibitors for the Treatment of Acute Myeloid Leukemia.
Novatcheva ED; Anouty Y; Saunders I; Mangan JK; Goodman AM
Clin Lymphoma Myeloma Leuk; 2022 Mar; 22(3):e161-e184. PubMed ID: 34649791
[TBL] [Abstract][Full Text] [Related]
13. [Sorafenib - induced thyroiditis in patient with a relapse of acute myelomonocytic leukemia with FLT3-ITD mutation].
Balzhanova YB; Parovichnikova EN; Sokolov AN; Ryzhko VV; Samtsova MA; Gribanova EO
Ter Arkh; 2019 Aug; 91(8):93-97. PubMed ID: 32598759
[TBL] [Abstract][Full Text] [Related]
14. ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia presenting in an infant: an entity distinct from JMML.
Spitzer B; Dela Cruz FS; Ibanez Sanchez GD; Zhang Y; Xiao W; Benayed R; Markova A; Rodriguez-Sanchez MI; Bouvier N; Roshal M; Kung AL; Shukla N
Blood Adv; 2021 Apr; 5(7):1899-1902. PubMed ID: 33792628
[TBL] [Abstract][Full Text] [Related]
15. Juvenile myelomonocytic leukemia with less aggressive clinical course and KRAS mutation.
Imamura M; Imai C; Takachi T; Nemoto T; Tanaka A; Uchiyama M
Pediatr Blood Cancer; 2008 Oct; 51(4):569. PubMed ID: 18561174
[No Abstract] [Full Text] [Related]
16. A novel tescalcin-sodium/hydrogen exchange axis underlying sorafenib resistance in FLT3-ITD+ AML.
Man CH; Lam SS; Sun MK; Chow HC; Gill H; Kwong YL; Leung AY
Blood; 2014 Apr; 123(16):2530-9. PubMed ID: 24608976
[TBL] [Abstract][Full Text] [Related]
17. Mutational analysis of SHOC2, a novel gene for Noonan-like syndrome, in JMML.
Flotho C; Batz C; Hasle H; Bergsträsser E; van den Heuvel-Eibrink MM; Zecca M; Niemeyer CM; Zenker M
Blood; 2010 Jan; 115(4):913. PubMed ID: 20110435
[No Abstract] [Full Text] [Related]
18. Does SPRED1 contribute to leukemogenesis in juvenile myelomonocytic leukemia (JMML)?
Batz C; Hasle H; Bergsträsser E; van den Heuvel-Eibrink MM; Zecca M; Niemeyer CM; Flotho C;
Blood; 2010 Mar; 115(12):2557-8. PubMed ID: 20339110
[No Abstract] [Full Text] [Related]
19. Adults with germline CBL mutation complicated with juvenile myelomonocytic leukemia at infancy.
Muraoka M; Okuma C; Kanamitsu K; Ishida H; Kanazawa Y; Washio K; Seki M; Kato M; Takita J; Sato Y; Ogawa S; Tsukahara H; Oda M; Shimada A
J Hum Genet; 2016 Jun; 61(6):523-6. PubMed ID: 26911351
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib in Relapsed AML With FMS-Like Receptor Tyrosine Kinase-3 Internal Tandem Duplication Mutation.
Giri S; Hamdeh S; Bhatt VR; Schwarz JK
J Natl Compr Canc Netw; 2015 May; 13(5):508-14. PubMed ID: 25964636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
